Search research articles
Contact Us
Filters
Showing results (1-10 of 40) with videos related to
Page
of 4
Sort By:
Antimicrobial Agents and Chemotherapy
|
June 10, 2026
Pharmacokinetic-pharmacodynamic modeling using combined time-kill data for meropenem and colistin or polymyxin B combination effects in <i>Acinetobacter baumannii</i>
Hiie Soeorg, Sihong Lyu, Frank Kloprogge, et al.
Frontiers in Antibiotics
|
January 16, 2025
Implications of drug-induced phenotypical resistance: Is isoniazid radicalizing <i>M. tuberculosis</i>?
Rjh Hammond, Frank Kloprogge, O Della Pasqua, et al.
Antibiotics (Basel, Switzerland)
|
December 24, 2021
Improving the Drug Development Pipeline for Mycobacteria: Modelling Antibiotic Exposure in the Hollow Fibre Infection Model
Arundhati Maitra, Priya Solanki, Zahra Sadouki, et al.
Toxics
|
March 27, 2024
Antibiotic Residues in UK Foods: Exploring the Exposure Pathways and Associated Health Risks
Jegak Seo, Frank Kloprogge, Andrew M Smith, et al.
The Journal of Antimicrobial Chemotherapy
|
September 11, 2019
Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?
Frank Kloprogge, Robert Hammond, Andrew Copas, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
November 15, 2020
Population Pharmacokinetics of Intraventricular Vancomycin in Neonatal Ventriculitis, A Preterm Pilot Study
Jaya Madhura Parasuraman, Frank Kloprogge, Joseph Frank Standing, et al.
Scientific Reports
|
September 15, 2019
Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection
Frank Kloprogge, Robert Hammond, Karin Kipper, et al.
Scientific Reports
|
October 31, 2024
The impact of physiological state and environmental stress on bacterial load estimation methodologies for Mycobacterium tuberculosis
Arundhati Maitra, Marie Wijk, Hasmik Margaryan, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
May 4, 2020
Ethambutol disposition in humans: Challenges and limitations of whole-body physiologically-based pharmacokinetic modelling in early drug development
Letizia Carrara, Paolo Magni, Donato Teutonico, et al.
The AAPS Journal
|
July 12, 2014
Statistical power calculations for mixed pharmacokinetic study designs using a population approach
Frank Kloprogge, Julie A Simpson, Nicholas P J Day, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 40) with videos related to
Sort By:
Page
of 4
Antimicrobial Agents and Chemotherapy
|
June 10, 2026
Pharmacokinetic-pharmacodynamic modeling using combined time-kill data for meropenem and colistin or polymyxin B combination effects in <i>Acinetobacter baumannii</i>
Hiie Soeorg, Sihong Lyu, Frank Kloprogge, et al.
Frontiers in Antibiotics
|
January 16, 2025
Implications of drug-induced phenotypical resistance: Is isoniazid radicalizing <i>M. tuberculosis</i>?
Rjh Hammond, Frank Kloprogge, O Della Pasqua, et al.
Antibiotics (Basel, Switzerland)
|
December 24, 2021
Improving the Drug Development Pipeline for Mycobacteria: Modelling Antibiotic Exposure in the Hollow Fibre Infection Model
Arundhati Maitra, Priya Solanki, Zahra Sadouki, et al.
Toxics
|
March 27, 2024
Antibiotic Residues in UK Foods: Exploring the Exposure Pathways and Associated Health Risks
Jegak Seo, Frank Kloprogge, Andrew M Smith, et al.
The Journal of Antimicrobial Chemotherapy
|
September 11, 2019
Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?
Frank Kloprogge, Robert Hammond, Andrew Copas, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
November 15, 2020
Population Pharmacokinetics of Intraventricular Vancomycin in Neonatal Ventriculitis, A Preterm Pilot Study
Jaya Madhura Parasuraman, Frank Kloprogge, Joseph Frank Standing, et al.
Scientific Reports
|
September 15, 2019
Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection
Frank Kloprogge, Robert Hammond, Karin Kipper, et al.
Scientific Reports
|
October 31, 2024
The impact of physiological state and environmental stress on bacterial load estimation methodologies for Mycobacterium tuberculosis
Arundhati Maitra, Marie Wijk, Hasmik Margaryan, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
May 4, 2020
Ethambutol disposition in humans: Challenges and limitations of whole-body physiologically-based pharmacokinetic modelling in early drug development
Letizia Carrara, Paolo Magni, Donato Teutonico, et al.
The AAPS Journal
|
July 12, 2014
Statistical power calculations for mixed pharmacokinetic study designs using a population approach
Frank Kloprogge, Julie A Simpson, Nicholas P J Day, et al.
Page
of 4